Steinert Disease clinical trials at University of California Health

1 research study open to eligible people

Global Study of Del-desiran for the Treatment of DM1
open to eligible people ages 16-65
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
at UCLA UCSD

Last updated: December 2, 2024